![]() | Only 14 pages are availabe for public view |
Abstract Hormone-refractory prostate cancer (HRPC) is a very heterogeneous disease. It includes different patient cohorts with significantly different median survival times, the precise definition of recurrent or relapsed CaP remains controversial and several groups have recently published practical recommendations for defining HRPC. |